Boston Scientific (BSX) AI Stock Analysis

• Market Cap: $154.32B
• Dividend Yield: N/A
• Average Volume (3M): 6.94M
• Price to Earnings (P/E): 61.4
• Beta (1Y): 0.81
• Revenue Growth: 21.45%
• EPS Growth: 36.19%
• Country: US
• Employees: 53,000
• Sector: Healthcare
• Sector Strength: 49
• Industry: Medical - Devices
• EPS (TTM): 0.75
• Shares Outstanding: 1,481,751,600
• 10 Day Avg. Volume: 5,910,472
• 30 Day Avg. Volume: 6,939,017
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.11
• Enterprise Value/Revenue: 9.80
• Enterprise Value/Gross Profit: 15.85
• Enterprise Value/Ebitda: 41.37
• 1Y Price Target: $125.09
• Price Target Upside: 21.25% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 23

• Rating: 73 Outperform
• Price Target: $115.00 ▲(11.47% Upside)

Boston Scientific's overall stock score reflects strong financial performance and a positive earnings call, highlighting robust growth and strategic initiatives. However, the high P/E ratio suggests potential overvaluation, and mixed technical indicators indicate a cautious outlook. The discontinuation of the ACURATE valve systems presents a challenge, but the company's increased guidance and strategic focus on high-demand segments support a favorable long-term perspective.

Positive Factors

Earnings

Boston Scientific reported Q2 revenue and EPS ahead of expectations due to strong performance in PFA and Watchman products.

Growth Outlook

BSX raised its 2025 organic growth guidance to 14-15%, which is higher than previous estimates.

Product Innovation

The label expansion for Watchman to include the option to use Intracardiac Echocardiography (ICE) can materially speed up the procedure as it removes the need for general anesthesia.

Negative Factors

Product Advisory

Boston Scientific issued a physician advisory letter highlighting calcification risk in older-generation ePTFE-coated ENDOTAK RELIANCE defibrillation leads.

Product Discontinuation

Management anticipates an impact on Interventional Cardiology due to the neo2 discontinuation.

Sales Impact

The adjusted income statement had a $100m impact in Q2 with the majority of this being inventory charges and the rest being sales returns.

Boston Scientific Business Overview & Revenue Model

Company Description

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

How the Company Makes Money

Boston Scientific generates revenue primarily through the sale of its medical devices across multiple therapeutic areas. The company’s revenue model is primarily based on direct sales to hospitals, healthcare facilities, and clinics, as well as through partnerships with various distributors. Key revenue streams include sales from cardiovascular devices, which encompass coronary and peripheral interventions, as well as rhythm management products such as implantable cardioverter-defibrillators and pacemakers. Additionally, Boston Scientific benefits from recurring revenue through the sale of consumable products and accessories needed for procedures using their devices. The company also invests in research and development to innovate and expand its product offerings, which can lead to increased market share and revenue growth. Strategic partnerships with healthcare providers and co-development agreements with other medical technology firms further enhance its revenue potential by broadening its product portfolio and market reach.

Boston Scientific Financial Statement Overview

Summary

Boston Scientific demonstrates strong financial performance with consistent revenue growth, solid profitability, and efficient cash flow management. The company's balanced approach between leveraging debt and maximizing equity returns supports its strategic growth initiatives in the medical devices sector. However, attention to further debt reduction could enhance financial resilience.

Income Statement

Boston Scientific has demonstrated robust growth in its revenue, with a notable TTM (Trailing-Twelve-Months) increase of 4.81% compared to the previous year. The company maintains strong gross and net profit margins at 67.15% and 11.57% respectively, indicating efficient cost management and profitability. The EBIT and EBITDA margins are solid at 17.52% and 21.65%, reflecting operational efficiency. Overall, the company shows a positive growth trajectory in the medical devices industry.

Balance Sheet

The balance sheet reflects a healthy financial position with a Debt-to-Equity ratio of 0.51, showing manageable leverage. The Return on Equity (ROE) stands at a strong 9.15%, indicating effective utilization of shareholders' equity. The Equity Ratio is 55.33%, suggesting a stable asset base supported by equity. Overall, the company maintains a strong balance between debt and equity, although there is room for improvement in reducing debt levels.

Cash Flow

Boston Scientific exhibits strong cash flow management with a Free Cash Flow growth rate of 8.62%, indicating improved cash generation. The Operating Cash Flow to Net Income ratio is 1.88, demonstrating the company's ability to convert income into cash efficiently. The Free Cash Flow to Net Income ratio is 1.41, reflecting good cash flow productivity. Overall, the company shows robust cash flow health, supporting its financial stability and operational needs.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	17.55B	16.75B	14.24B	12.68B	11.89B	9.91B
Gross Profit	10.85B	10.27B	8.83B	7.71B	7.46B	5.58B
EBITDA	4.16B	3.94B	3.45B	2.74B	2.52B	1.51B
Net Income	2.03B	1.85B	1.59B	698.00M	1.04B	-82.00M
Balance Sheet
Total Assets	40.14B	39.40B	35.14B	32.47B	32.23B	30.78B
Cash, Cash Equivalents and Short-Term Investments	725.00M	414.00M	865.00M	928.00M	1.93B	1.73B
Total Debt	11.71B	11.15B	9.49B	9.28B	9.45B	9.54B
Total Liabilities	17.69B	17.39B	15.61B	14.90B	15.61B	15.45B
Stockholders Equity	22.21B	21.77B	19.28B	17.57B	16.62B	15.33B
Cash Flow
Free Cash Flow	2.87B	2.65B	1.70B	914.00M	1.32B	1.13B
Operating Cash Flow	3.81B	3.44B	2.50B	1.53B	1.87B	1.51B
Investing Cash Flow	-5.90B	-5.69B	-2.57B	-2.01B	-1.60B	-411.00M
Financing Cash Flow	478.00M	1.81B	5.00M	-548.00M	-95.00M	293.00M

Boston Scientific Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 103.17
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BSX, the sentiment is Neutral. The current price of 103.17 is below the 20-day moving average (MA) of 104.62, below the 50-day MA of 103.56, and above the 200-day MA of 98.77, indicating a neutral trend. The MACD of -0.30 indicates Positive momentum. The RSI at 46.37 is Neutral, neither overbought nor oversold. The STOCH value of 32.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BSX.

Boston Scientific Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ABT	79 Outperform	$225.01B	16.17	31.01%	1.76%	5.85%	152.28%
MDT	77 Outperform	$117.85B	25.45	9.49%	3.02%	3.62%	31.18%
EW	76 Outperform	$45.90B	53.43	15.71%	―	-5.23%	-39.83%
BSX	73 Outperform	$154.32B	61.40	11.71%	―	21.45%	36.19%
DXCM	73 Outperform	$31.36B	56.67	22.83%	―	9.30%	-14.95%
SYK	72 Outperform	$146.01B	50.54	14.25%	0.87%	11.36%	-15.66%
Sector *	60 Neutral	HK$18.32B	5.45	-4.00%	3.31%	9.92%	-18.97%

Boston Scientific Corporate Events

Boston Scientific Discontinues Aortic Valve Systems

On May 28, 2025, Boston Scientific announced the discontinuation of its ACURATE neo2™ and ACURATE Prime™ Aortic Valve Systems, ceasing global sales and halting pursuit of FDA approval due to increased regulatory demands. Despite the financial implications, the company expects to meet its sales and earnings guidance for 2025, though it is withholding reaffirmation of its GAAP EPS guidance until further updates in its second quarter earnings call.

The most recent analyst rating on (BSX) stock is a Buy with a $113.00 price target. To see the full list of analyst forecasts on Boston Scientific stock, see the BSX Stock Forecast page.